-
错配修复(mismatch repair, MMR)系统是进化过程中高度保守的系统, 研究发现, 从酵母到人类的MMR同源基因具有高度保守性。MMR系统能修复细胞中DNA的碱基-碱基对的错配, 从而消除点突变、插入或删除环突变, 达到消除阅读框架位移突变的目的, 起到保持基因组稳定的作用。这些突变形式主要出现在DNA复制的细胞周期S期, 因此MMR系统可以降低DNA复制的错配率。研究表明, MMR系统在肿瘤的发生、增殖、侵袭、转移、预后、对放化疗反应等方面都起到很重要的作用。
错配修复系统缺陷对肿瘤放化疗的影响
The effect of mismatch repair deficiency on chemotherapy and radiotherapy in tumors
-
摘要: 在肿瘤干细胞和增殖性肿瘤细胞中,广泛存在错配修复(MMR)系统的功能缺失。对于接受化疗的肿瘤,若MMR缺失,可导致细胞绕过细胞周期的G2/S期循环阻滞,产生对化疗药物的抗性。在临床上,即使是O6-甲基鸟嘌呤-DNA甲基转移酶阴性的胶质瘤细胞也会因MMR的缺失,对替莫唑胺产生抗性。对于接受放射治疗的肿瘤,MMR缺失的作用表现为相互矛盾的两个方面:首先,MMR缺失可导致肿瘤细胞对辐射抗性的提高,细胞不出现凋亡和自吞噬;另一方面,预先给予放射增敏剂5-碘-2'-脱氧尿苷(IUdR)等药物后,MMR的缺失会导致DNA中掺杂大量未被修复的IUdR等基团,从而提高肿瘤细胞的辐射敏感性。Abstract: It is very common phenomenon that mismatch repair(MMR)deficiency in various tumors, both stem cells and proliferation cells.With MMR deficiency, the cells treated by chemotherapy drugs passed the G2/S arrest and became resistant to the drugs.In the clinical trial, even in the glioma with negative O6-methylguanine-DNA methyltransferase expression show the resistance to Temozolomide.The MMR deficiency cells treated by radiotherapy show two contradictory behaviors.MMR deficiency enhanced the cells resistance to radiation, for cells show less apoptosis or autophagy.On the other hand, pretreated with radiation enhancer, such as 5-iodo-2'-deoxyuridine(IUdR), resulting in more IUdR-DNA unrepaired cells and increasing the sensitivity to radiation.
-
Key words:
- Base pair mismatch /
- DNA repair /
- Radiation tolerance /
- Drug resistance, neoplasm
-
[1] Kinsella TJ. Coordination of DNA mismatch repair and base excision repair processing of chenotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res, 2009, 15(6): 1853-1859. doi: 10.1158/1078-0432.CCR-08-1307 [2] Vaish M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer, 2007, 6: 26. doi: 10.1186/1476-4598-6-26 [3] Zeng X, Kinsella TJ. A novel role for DNA mismatch repair and the autophagic processing of chemotherapy drug in human tumor cells. Autophagy, 2007, 3(4): 368-370. doi: 10.4161/auto.4205 [4] O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis, 2006, 27(4): 682-692. doi: 10.1093/carcin/bgi298 [5] Yip S, Miao J, Cahill DP, et al. MSH6 mutation arise in glioblastomas during temozolomide therapy and mediated temozolomide resistance. Clin Cancer Res, 2009, 15(14): 4622-4629. doi: 10.1158/1078-0432.CCR-08-3012 [6] Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res, 2006, 66(8): 3987-3991. doi: 10.1158/0008-5472.CAN-06-0127 [7] Yan T, SeoY, Kinsella TJ. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res, 2009, 15(22): 6912-6920. doi: 10.1158/1078-0432.CCR-09-1698 [8] Shahi A, Lee JH, Kang Y, et al. Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair. Nucleic Acids Res, 2011, 39(6): 2130-2143. doi: 10.1093/nar/gkq1095 [9] Kinsella TJ, Kinsella MT, Seo Y, et al. 5-iodo-2-pyrimidinone-2'-deoxyribose(IPdR)-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts. Int J Radiat Oncol Biol Phys, 2007, 69(4): 1254-1261. doi: 10.1016/j.ijrobp.2007.08.004 [10] Gerson SL, Reese J, Kenyon J. DNA repair in stem cell maintenance and conversion to cancer stem cells. Ernst Schering Found Symp Proc, 2007, 5: 231-244. [11] Rodríquez-Jimémez FJ, Moreno-Manzano V, Lucas-Dominquez R, et al. Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cell. Stem Cells, 2008, 26(8): 2052-2062. doi: 10.1634/stemcells.2007-1016 [12] Jiricny J. The miltifaceted mismatch-repair system. Nat Rev Mol Cell Biol, 2006, 7(5): 335-346. [13] Adamson AW, Beardsley DI, Kim WJ, et al. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell, 2005, 16(3): 1513-1526. doi: 10.1091/mbc.e04-02-0089 [14] Yoshioka K, Yoshioka Y, Hsieh P. ATR kinase activation mediated by Mut Sα and Mut Lα in responseto cytotoxic O6-methylguanine adducts. Mol Cell, 2006, 22(4): 501-510. doi: 10.1016/j.molcel.2006.04.023 [15] Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 2008, 8(3): 193-204. doi: 10.1038/nrc2342 [16] Schulz CA, Mehta MP, Badie B, et al. Continuous 28-days iodo-deoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. Int J Radiat Oncol Biol Phys, 2004, 59(4): 1107-1115. doi: 10.1016/j.ijrobp.2003.12.007
计量
- 文章访问数: 947
- HTML全文浏览量: 411
- PDF下载量: 1